In utero exposure to protease inhibitor-based antiretroviral regimens delays growth and developmental milestones in mice.
Animals
Anti-HIV Agents
/ administration & dosage
Atazanavir Sulfate
/ administration & dosage
Developmental Disabilities
/ chemically induced
Dideoxynucleosides
/ administration & dosage
Emtricitabine
/ administration & dosage
Exploratory Behavior
/ drug effects
Female
Fetal Growth Retardation
/ chemically induced
Growth Disorders
/ chemically induced
HIV Protease Inhibitors
/ administration & dosage
Hand Strength
Homing Behavior
/ drug effects
Lamivudine
/ administration & dosage
Male
Mice
Mice, Inbred C57BL
Pregnancy
Prenatal Exposure Delayed Effects
Random Allocation
Reflex, Abnormal
Reflex, Righting
/ drug effects
Sensation Disorders
/ chemically induced
Taxis Response
/ drug effects
Tenofovir
/ administration & dosage
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
07
2020
accepted:
03
11
2020
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
5
1
2021
Statut:
epublish
Résumé
Antiretroviral therapy (ART) in pregnancy has dramatically reduced HIV vertical transmission rates. Consequently, there is a growing number of children that are HIV exposed uninfected (CHEUs). Studies suggest that CHEUs exposed in utero to ART may experience developmental delays compared to their peers. We investigated the effects of in utero ART exposure on perinatal neurodevelopment in mice, through assessment of developmental milestones. Developmental milestone tests (parallel to reflex testing in human infants) are reflective of brain maturity and useful in predicting later behavioral outcomes. We hypothesized that ART in pregnancy alters the in utero environment and thereby alters developmental milestone outcomes in pups. Throughout pregnancy, dams were treated with boosted-atazanavir combined with either abacavir/lamivudine (ATV/r/ABC/3TC), or tenofovir/emtricitabine (ATV/r/TDF/FTC), or water as control. Pups were assessed daily for general somatic growth and on a battery of tests for primitive reflexes including surface-righting, negative-geotaxis, cliff-aversion, rooting, ear-twitch, auditory-reflex, forelimb-grasp, air-righting, behaviors in the neonatal open field, and olfactory test. In utero exposure to either ART regimen delayed somatic growth in offspring and evoked significant delays in the development of negative geotaxis, cliff-aversion, and ear-twitch reflexes. Exposure to ATV/r/ABC/3TC was also associated with olfactory deficits in male and forelimb grasp deficits in female pups. To explore whether delays persisted into adulthood we assessed performance in the open field test. We observed no significant differences between treatment arm for males. In females, ATV/r/TDF/FTC exposure was associated with lower total distance travelled and less ambulatory time in the centre, while ATV/r/ABC/3TC exposure was associated with higher resting times compared to controls. In utero PI-based ART exposure delays the appearance of primitive reflexes that involve vestibular and sensory-motor pathways in a mouse model. Our findings suggest that ART could be disrupting the normal progress/maturation of the underlying neurocircuits and encourage further investigation for underlying mechanisms.
Identifiants
pubmed: 33211746
doi: 10.1371/journal.pone.0242513
pii: PONE-D-20-20335
pmc: PMC7676697
doi:
Substances chimiques
Anti-HIV Agents
0
Dideoxynucleosides
0
HIV Protease Inhibitors
0
Lamivudine
2T8Q726O95
Atazanavir Sulfate
4MT4VIE29P
Tenofovir
99YXE507IL
Emtricitabine
G70B4ETF4S
abacavir
WR2TIP26VS
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0242513Subventions
Organisme : CIHR
Pays : Canada
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose in relation to this work. LS reports personal fees from ViiV Healthcare for participation in a Women and Transgender Think Tank. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
AIDS. 2012 Mar 27;26(6):757-63
pubmed: 22210635
Clin Infect Dis. 2004 Mar 1;38(5):743-53
pubmed: 14986261
Lancet. 2011 Oct 8;378(9799):1325-38
pubmed: 21944375
Front Immunol. 2016 May 06;7:164
pubmed: 27199989
Pharmacol Biochem Behav. 2000 Nov;67(3):511-7
pubmed: 11164081
Neuroscience. 2010 Oct 13;170(2):514-22
pubmed: 20603192
EMBO J. 2012 Feb 1;31(3):640-53
pubmed: 22068054
Clin Exp Immunol. 2014 Apr;176(1):11-22
pubmed: 24325737
Behav Brain Res. 2015;287:146-55
pubmed: 25823761
Mitochondrion. 2004 Jul;4(2-3):153-62
pubmed: 16120380
Horm Res Paediatr. 2010;73(1):6-14
pubmed: 20190535
Dialogues Clin Neurosci. 2016 Dec;18(4):459-464
pubmed: 28179817
Front Immunol. 2016 Aug 19;7:310
pubmed: 27594857
Pediatr Endocrinol Rev. 2005 Mar;2(3):372-7
pubmed: 16429113
Pediatr Infect Dis J. 2013 Jun;32(6):648-55
pubmed: 23340561
Mol Brain. 2008 Dec 17;1:22
pubmed: 19091092
Pediatr Infect Dis J. 2013 Oct;32(10):e406-13
pubmed: 24067563
JAMA Pediatr. 2015 Jan;169(1):48-55
pubmed: 25383770
Curr Opin HIV AIDS. 2016 Sep;11(5):465-476
pubmed: 27716731
Toxicol Appl Pharmacol. 2004 Sep 1;199(2):151-61
pubmed: 15313587
Antiviral Res. 2018 Nov;159:45-54
pubmed: 30236532
J Infect Dis. 2015 Jan 1;211(1):10-8
pubmed: 25030058
Neurotoxicol Teratol. 1999 Jan-Feb;21(1):29-40
pubmed: 10023799
Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):406-413
pubmed: 27840304
Pediatrics. 2012 Nov;130(5):e1326-44
pubmed: 23118140
AIDS. 2004 Apr 30;18(7):1013-21
pubmed: 15096804
J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):131-8
pubmed: 21124227
Neurotoxicol Teratol. 1999 Jul-Aug;21(4):365-73
pubmed: 10440480
AIDS. 2018 Nov 13;32(17):2583-2592
pubmed: 30134292
Front Immunol. 2016 May 23;7:199
pubmed: 27242802
J AIDS Immune Res. 2016;1(1):
pubmed: 28459118
Lancet. 1999 Sep 25;354(9184):1084-9
pubmed: 10509500
Teratology. 2001 Jan;63(1):26-37
pubmed: 11169552
Neurotoxicol Teratol. 2015 Sep-Oct;51:1-11
pubmed: 26171567
Int J Dev Neurosci. 2008 Aug;26(5):423-34
pubmed: 18423945
Prog Neurobiol. 2013 Jul-Aug;106-107:1-16
pubmed: 23583307
AIDS. 2014 Jul;28 Suppl 3:S251-9
pubmed: 24991898
AIDS Care. 2017 Oct;29(10):1302-1308
pubmed: 28482682
Toxicol Pathol. 2017 Aug;45(6):705-744
pubmed: 28891434
BMC Pregnancy Childbirth. 2014 Jan 08;14:7
pubmed: 24397463
Front Cell Neurosci. 2011 Nov 21;5:24
pubmed: 22125512
J Vis Exp. 2017 Apr 24;(122):
pubmed: 28518104
Toxicol Pathol. 2014 Jul;42(5):811-22
pubmed: 24067671
Brain Dev. 2000 Oct;22(7):411-6
pubmed: 11102724
Pediatrics. 2018 Feb;141(2):
pubmed: 29374109
JAMA. 2017 Apr 18;317(15):1553-1562
pubmed: 28418479
AIDS. 2016 May 15;30(8):1267-78
pubmed: 26867136
Neuropsychopharmacology. 2005 Jan;30(1):80-9
pubmed: 15238991
Pediatrics. 2004 Nov;114(5):e598-603
pubmed: 15492359
Int J Pediatr. 2012;2012:191562
pubmed: 22778756
Paediatr Child Health. 2012 Dec;17(10):561-8
pubmed: 24294064
AIDS. 2007 May 11;21(8):929-38
pubmed: 17457086
Physiol Behav. 1994 Oct;56(4):659-63
pubmed: 7800729
Lancet Child Adolesc Health. 2019 Apr;3(4):234-244
pubmed: 30773459
Neurosci Biobehav Rev. 2008 Sep;32(7):1315-25
pubmed: 18555528
Neuropediatrics. 1997 Dec;28(6):296-306
pubmed: 9453026
Autoimmun Rev. 2006 Nov;6(1):54-60
pubmed: 17110318
Curr Opin Pediatr. 2015 Apr;27(2):233-9
pubmed: 25635584
Neuropsychopharmacology. 2014 Oct;39(11):2662-72
pubmed: 24903652
Curr HIV/AIDS Rep. 2019 Dec;16(6):501-513
pubmed: 31732866